Abstract:Purpose
Because preapproval clinical trials typically exclude pregnant women, the evidence on drug safety during pregnancy required to inform drug labeling must come from postapproval controlled observational studies. Common designs have included pregnancy registries and case‐control studies. Recently, pregnancy cohorts nested within healthcare utilization databases are increasingly being used. Despite clear advantages, these databases share some important limitations that may threaten the validity of studies … Show more
“…For example, in our cohort, approximately 35 000 pregnancies had codes from conflicting outcome types, and thus, specialized algorithms were needed to assign the final pregnancy outcome. Previous studies have varied widely on this assignment . We developed our algorithms based on prior literature, claims reviews of a sample of pregnancies from each definition, further cycles of optimization, and finally removal of improbable or unclassifiable pregnancies.…”
Section: Discussionmentioning
confidence: 99%
“…Within a population of women ages 12 to 55, with nonmissing enrollee IDs, and inpatient or outpatient claims between January 1, 2011 and September 30, 2015, we searched inpatient and outpatient files for International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnosis, ICD‐9‐CM procedure, Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and Diagnosis Related Group (DRG) codes relating to the end of pregnancy (e‐Appendix A). End‐of‐pregnancy codes were codes that signaled that the pregnancy had ended (eg, “normal delivery”) and were categorized into one of eight outcomes (livebirth, stillbirth, mixed birth [at least one infant is a livebirth and at least one is a stillbirth], spontaneous abortion [SAB], elective termination, unspecified abortion, ectopic or molar pregnancy, and unclassified deliveries). Codes that signaled a delivery but did not indicate live or stillbirth status (eg, “caesarean delivery”) were classified as “unclassified delivery” codes.…”
Section: Methodsmentioning
confidence: 99%
“…Increasingly, administrative databases are being used for postmarketing surveillance in pregnancy. 1 An alternative to traditional pregnancy registries, these databases are often large, have prospective prescription recording, and are less costly for research than ad hoc registries. 2 However, administrative databases can be prone to misclassification and missing information.…”
Section: Introductionmentioning
confidence: 99%
“…3 Specifically, in pregnancy studies, identifying early losses and dates of conception can be challenging. [4][5][6][7] Indeed, limitations of prior work include missing mother-infant linkages, 5,[8][9][10] exclusion of pregnancy losses, 9,11,12 crude classification of pregnancy types, 1,8,13 and arbitrary gestational age assignments. 8,10,13,14 The development and validation of algorithms to identify pregnancies in administrative data is needed to improve the validity of these cohorts for future research.…”
Section: Introductionmentioning
confidence: 99%
“…and Diagnosis Related Group (DRG) codes relating to the end of pregnancy (e-Appendix A). 1,[6][7][8][11][12][13]31,32 End-of-pregnancy codes were codes that signaled that the pregnancy had ended (eg, "normal delivery") and…”
Purpose
The purpose of the study is to develop an algorithm to identify pregnancies in administrative databases and apply it to assess pregnancy rates and outcomes in women prescribed isotretinoin or tretinoin.
Methods
Using the 2011 to 2015 Truven Health MarketScan Database, we identified pregnancies, including losses and terminations. In a cohort design, nonpregnant women filling a prescription for isotretinoin or tretinoin were matched to five women without either prescription. Women were followed for 365 days or until conception, medication discontinuation, or enrollment discontinuation (“prescription episode”). Rates of pregnancy, risks of pregnancy losses, and prevalence of infant malformations at birth were assessed by exposure.
Results
We identified 2 179 192 livebirths, 8434 stillbirths, 2521 mixed births, 415 110 spontaneous abortions, 124 556 elective terminations, and 8974 unspecified abortions. There were 86 834 isotretinoin and 973 587 tretinoin episodes, matched to 5 302 105 unexposed women. Pregnancy rates were 3 (isotretinoin), 19 (tretinoin), and 34 (unexposed) per 1000 person‐years. Risk of spontaneous pregnancy losses were similar; however, terminations were more common in the isotretinoin‐exposed (28% [95% CI: 21%‐36%]) than the tretinoin‐exposed (10% [95% CI: 9%‐11%]) or unexposed pregnancies (6%). Malformations occurred in 4.5% (95% CI: 3.5%‐5.6%) of the tretinoin‐exposed pregnancies and 4.2% of the unexposed pregnancies (adjusted odds ratio: 1.16 [95% CI: 0.85‐1.58]); isotretinoin‐exposed births were too few to assess malformations.
Conclusions
Administrative databases can complement risk evaluation and mitigation strategies (REMS) for known teratogens and contribute to safety surveillance for other medications. Here, isotretinoin‐exposed pregnancy rates were low, but existent, and many pregnancies were terminated. Tretinoin exposure was not associated with a meaningfully elevated risk of losses or malformations as compared with unexposed pregnancies.
“…For example, in our cohort, approximately 35 000 pregnancies had codes from conflicting outcome types, and thus, specialized algorithms were needed to assign the final pregnancy outcome. Previous studies have varied widely on this assignment . We developed our algorithms based on prior literature, claims reviews of a sample of pregnancies from each definition, further cycles of optimization, and finally removal of improbable or unclassifiable pregnancies.…”
Section: Discussionmentioning
confidence: 99%
“…Within a population of women ages 12 to 55, with nonmissing enrollee IDs, and inpatient or outpatient claims between January 1, 2011 and September 30, 2015, we searched inpatient and outpatient files for International Classification of Diseases, Ninth Revision, Clinical Modification (ICD‐9‐CM) diagnosis, ICD‐9‐CM procedure, Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System (HCPCS), and Diagnosis Related Group (DRG) codes relating to the end of pregnancy (e‐Appendix A). End‐of‐pregnancy codes were codes that signaled that the pregnancy had ended (eg, “normal delivery”) and were categorized into one of eight outcomes (livebirth, stillbirth, mixed birth [at least one infant is a livebirth and at least one is a stillbirth], spontaneous abortion [SAB], elective termination, unspecified abortion, ectopic or molar pregnancy, and unclassified deliveries). Codes that signaled a delivery but did not indicate live or stillbirth status (eg, “caesarean delivery”) were classified as “unclassified delivery” codes.…”
Section: Methodsmentioning
confidence: 99%
“…Increasingly, administrative databases are being used for postmarketing surveillance in pregnancy. 1 An alternative to traditional pregnancy registries, these databases are often large, have prospective prescription recording, and are less costly for research than ad hoc registries. 2 However, administrative databases can be prone to misclassification and missing information.…”
Section: Introductionmentioning
confidence: 99%
“…3 Specifically, in pregnancy studies, identifying early losses and dates of conception can be challenging. [4][5][6][7] Indeed, limitations of prior work include missing mother-infant linkages, 5,[8][9][10] exclusion of pregnancy losses, 9,11,12 crude classification of pregnancy types, 1,8,13 and arbitrary gestational age assignments. 8,10,13,14 The development and validation of algorithms to identify pregnancies in administrative data is needed to improve the validity of these cohorts for future research.…”
Section: Introductionmentioning
confidence: 99%
“…and Diagnosis Related Group (DRG) codes relating to the end of pregnancy (e-Appendix A). 1,[6][7][8][11][12][13]31,32 End-of-pregnancy codes were codes that signaled that the pregnancy had ended (eg, "normal delivery") and…”
Purpose
The purpose of the study is to develop an algorithm to identify pregnancies in administrative databases and apply it to assess pregnancy rates and outcomes in women prescribed isotretinoin or tretinoin.
Methods
Using the 2011 to 2015 Truven Health MarketScan Database, we identified pregnancies, including losses and terminations. In a cohort design, nonpregnant women filling a prescription for isotretinoin or tretinoin were matched to five women without either prescription. Women were followed for 365 days or until conception, medication discontinuation, or enrollment discontinuation (“prescription episode”). Rates of pregnancy, risks of pregnancy losses, and prevalence of infant malformations at birth were assessed by exposure.
Results
We identified 2 179 192 livebirths, 8434 stillbirths, 2521 mixed births, 415 110 spontaneous abortions, 124 556 elective terminations, and 8974 unspecified abortions. There were 86 834 isotretinoin and 973 587 tretinoin episodes, matched to 5 302 105 unexposed women. Pregnancy rates were 3 (isotretinoin), 19 (tretinoin), and 34 (unexposed) per 1000 person‐years. Risk of spontaneous pregnancy losses were similar; however, terminations were more common in the isotretinoin‐exposed (28% [95% CI: 21%‐36%]) than the tretinoin‐exposed (10% [95% CI: 9%‐11%]) or unexposed pregnancies (6%). Malformations occurred in 4.5% (95% CI: 3.5%‐5.6%) of the tretinoin‐exposed pregnancies and 4.2% of the unexposed pregnancies (adjusted odds ratio: 1.16 [95% CI: 0.85‐1.58]); isotretinoin‐exposed births were too few to assess malformations.
Conclusions
Administrative databases can complement risk evaluation and mitigation strategies (REMS) for known teratogens and contribute to safety surveillance for other medications. Here, isotretinoin‐exposed pregnancy rates were low, but existent, and many pregnancies were terminated. Tretinoin exposure was not associated with a meaningfully elevated risk of losses or malformations as compared with unexposed pregnancies.
A population-based cohort study previously evaluated the association between first-trimester exposure to the oral formulations of ondansetron and congenital malformations. After accounting for potential confounding variables, there was no significant association with congenital malformations overall or cardiac malformations, but a small increased risk of oral clefts could not be excluded. 1 Subsequent research has suggested that intravenous administration of ondansetron may be associated with greater risks of cardiac malformations and oral clefts. 2 Potential explanations for the apparent difference in teratogenic effect of intravenous compared with oral formulations include (1) residual confounding by indication and associated factors (eg, nutritional deficiencies) in women with hyperemesis severe enough to require intravenous medication, (2) higher doses administered intravenously vs orally, and (3) higher specificity for exposure because studies of oral use in health care utilization data are based on dispensed medication, and not all women may consume the medication as prescribed. We therefore conducted a follow-up study to examine the association between intravenous ondansetron and congenital malformations. Methods | The data source, study design, and analytic methods were the same as described in our previously published evaluation of oral ondansetron. 1 Briefly, we used a motherinfant-linked cohort nested in the 2000 to 2014 Medicaid Analytic eXtract. 3 The research was approved by the institutional review board of Brigham and Women's Hospital, with waiver of informed consent.
IMPORTANCETerbinafine is a commonly used antifungal agent, but safety data of its use in pregnancy are limited.OBJECTIVE To examine the association between oral and topical terbinafine exposure in pregnancy and the risk of major malformations and spontaneous abortion.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.